

Sienna signs lease for new premises to facilitate the execution of its strategic goal to become an IVD Hub

- Sienna advances its plans to become a hub for IVD test development and commercialisation
- New premises are located near CSIRO and the Monash Technology Precinct
- New manufacturing facilities for SIEN-NET™ product line to be built

Melbourne, Australia, 8 October 2019: [Sienna Cancer Diagnostics Ltd \(ASX: SDX\)](#) (“Sienna” or “the Company”), a medical technology company developing and commercialising innovative IVD tests, is expanding its operations and moving to a new location adjacent to CSIRO and the Monash Technology Precinct.

Sienna’s new premises will contain office space, research and development laboratories, as well as a manufacturing suite and warehouse facility for the SIEN-NET product line which is currently in development.

Sienna CEO Matthew Hoskin said “This move represents a significant progression for the Company. We will establish manufacturing for our cutting edge SIEN-NET technology, which is an important milestone. Additionally, we are preparing for the expansion of our development, manufacturing and commercialisation capabilities, in anticipation of bringing in new products as part of our technology expansion program. The move represents a key development in the implementation of our vision to become a hub for the development and launch of IVD tests from the university research bench to the global pathology market”.

The new location is ideally situated in the heart of a vibrant industry cluster in the south east region of Melbourne. This is a major centre of enterprise in the State and is known for its high tech industries and research facilities, including Monash University, the Monash Science Technology Research and Innovation Precinct, CSIRO and the Australian Synchrotron.

The move is expected to occur early in the new year, when construction of the new laboratory and manufacturing suites is completed.

ENDS

For further information, please contact:

Matthew Hoskin, CEO
Sienna Cancer Diagnostics
mhoskin@siennadiagnostics.com.au
+61 3 8288 2141

Kyahn Williamson
WE Buchan
sienna@we-buchan.com
+61 3 8866 1200



About Sienna Cancer Diagnostics

Sienna Cancer Diagnostics Ltd. ("the Company", or "Sienna") is an Australian medical technology company with operations in the United States and Australia, and distributors for its products in the United States, Europe, Asia and Latin America.

Sienna's vision is to become a hub for the development and commercialisation of *in-vitro* diagnostic (IVD) tests for the global pathology market. Our mission is to create a portfolio of products to bring to market much needed cancer diagnostic solutions, which will in turn generate additional revenue and long-term growth for Sienna's shareholders.

Sienna's strengths lie in the identification, development and commercialisation of novel IVD technologies that satisfy an unmet clinical / market need. Our first product is an antibody-based IVD test to detect the biomarker "hTERT". Sienna has taken the hTERT test from research, through development and manufacturing, to product registration and sales through a growing network of distribution partners.

The Company intends to fill an important gap in the Australian MedTech ecosystem, by providing a capable, efficient and effective development, manufacturing and commercial launch pathway for IVD technologies sourced from leading universities and research institutions.

As part of this technology expansion strategy, Sienna recently acquired a unique technology for the capture and isolation of target biomarkers in liquid biopsy samples. The sample preparation technology, known as SIEN-NET™, can more accurately and rapidly prepare samples for the liquid biopsy testing of a range of clinically useful biomarkers, including exosomes, lipids, proteins, and other molecular targets of interest.

We are focussed on growing revenues from the hTERT test, increasing market access through new distribution partnerships, commercialisation of the SIEN-NET™ product line, and expanding our product offerings with the addition of new technologies.

Forward Looking Statements

This announcement may contain forward-looking statements, which include all matters that are not historical facts. These forward-looking statements speak only as at the date of this announcement. These statements, by their nature, are subject to a number of known and unknown risks and uncertainties that could cause the actual results, performances and achievements to differ materially from any expected future results, performance or achievements expressed or implied by forward-looking statements. Without limitation, indications of, and guidance on, future earnings and financial position and performance are examples of forward-looking statements. No representation, warranty or assurance (express or implied) is given or made by Sienna that the forward-looking statements contained in this announcement are accurate, complete, reliable, or adequate or that they will be achieved or prove to be correct. Except for any statutory liability which cannot be excluded, each of

Sienna, its related companies and their respective directors, employees and advisers expressly disclaim any responsibility for the accuracy or completeness of the forward-looking statements and exclude all liability whatsoever (including negligence) for any direct or indirect loss or damage which may be suffered by any person as a consequence of any information in this presentation or any error or omission therefrom.

